sustol
sustol: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | Approved |
FDA Decisions
Frequently asked questions
Who is developing sustol?
sustol is being developed by HERON THERAPEUTICS, INC. /DE/.
What is sustol's latest FDA decision?
The most recent tracked FDA decision for sustol is Approval for 1 INDICATIONS AND USAGE SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated , dated August 9, 2016.
Get deeper analysis on sustol
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis